全球肿瘤医生网

欢迎来到全球肿瘤医生网!

当前位置:网站首页>>癌症分类>>肺癌» 正文

 

肺癌驱动基因及其靶向治疗药物

编辑:全球肿瘤医生网2017-09-26 16:11

 黄炎 ;杨继元 高影响力作者
Huang Yan, Yang Jiyuan( Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou 434000, China)机构地区:长江大学附属第一医院肿瘤科,荆州434000 高影响力机构出  处:《国际肿瘤学杂志》 CAS 2017年第44卷第1期 53-56页,共4页高影响力期刊《Journal of International Oncology》摘  要:随着肿瘤分子生物学的发展,针对肺癌驱动基因的分子靶向治疗已成为晚期肺癌不可或缺的一部分。目前最成功的例子就是针对表皮生长因子受体(EGFR)和间变性淋巴瘤激酶(ALK)的靶向治疗。现在越来越多的肺癌驱动基因突变已被发现,包括ROS1基因融合、成纤维细胞生长因子1扩增、KRAS、BRAF和PIK3 CA基因突变等。明确这些基因突变的频率及临床意义,对指导肺癌的临床治疗有着重要的意义。With the development of molecular biology of cancer,molecular targeted therapy which tar-geted the driver genes in lung cancer has become an inevitable part of the treatment of advanced lung cancer. The most successful examples of targeted therapy are targeting epidermal growth factor receptor (EGFR)and anaplastic lymphoma kinase (ALK).More and more driver genes have been discovered,including ROS1 gene fusion,fibroblast growth factor receptor 1 amplification,KRAS,BRAF,PIK3CA gene mutation and so on.It is meaningful for guiding the treatment of lung cancer that defines the mutation incidence and clinical significance of driver genes in lung cancer.关 键 词:肺肿瘤 驱动基因 靶向治疗Lung neoplasms Driver genes Targeted therapy分 类 号:R681 [医药、卫生 > 外科学 > 骨科学(运动系疾病、矫形外科学) > 骨骼疾病]高被引论文
作者简介:通信作者:杨继元,Email:yangjiyuanchina@163.com

参考文献(28篇)

  • [1]Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10. 3322/caac. 21338.
  • [2]Weinstein lB. Cancer. Addiction to oncogenes-the Achilles heal of cancer[J]. Science, 2002, 297(5578): 63-64.
  • [3]Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epi- demiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology ( PIonEER ) [J]. J Thorac Oncol, 2014, 9(2) : 154-162. DOI: 10. 1097/JTO. 0000000000000033.
  • [4]Arrieta O, Cardona AF, Martin C, et al. Updated frequency of EGFR and KRAS mutations in non-small-cell lung cancer in Latin America: the Latin-American consortium for the investigation of lung cancer (CLICaP) [ J 1. J Thorac Oncol, 2015, 10 (5) : 838-843. DOI: 10. 1097/JTO. 0000000000000481.
  • [5]Lee SY, Kim M J, Jin G, et al. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers[J]. JThoracOncol, 2010, 5(11): 1734-1740. DOI: 10. 1097/JTO. 0b013 e3181 f0beca.
  • [6]He M, Cape|letti M, Nafa K, et al. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma [ J ]. Clin Cancer Res, 2012, 18(6) : 1790-1797. DOI: 10. 1158/1078- 0432. CCR-11-2361.
  • [7]Yasuda H, Park E, Yun CH, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer [ J 1. Sci Transl Med, 2013, 5 (216) : 216ra177. DOI : 10.1126/scitranslmed. 3007205.
  • [8]Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EUR- TAC): a muhicentre, open-label, randomised phase 3 trial [ J]. Lancet Oncol, 2012, 13 (3) : 239-246. DOI: 10. 1016/S1470-2045 ( 11 ) 70393-X.
  • [9]Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single- agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung[ Jl. J C lin Oncol, 2012, 30 (10) : 1122-1128. DOI: 10. 1200/JCO. 2011.36. 8456.
  • [10]Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsEJ]. Sci Transl Med, 2011, 3(75) : 75ra26. DOI: 10. 1126/scitranslmed. 3002003.
  • [11]Ramalingam SS, Blackhall F, Krzakowski M, et al. Randomized phase 1] study of dacomitinib (PF-00299804), an irreversible pan- human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer[J]. J Clin Oncol, 2012, 30 (27) : 3337-3344. DOI : 10. 1200/JCO. 2011.40. 9433.
  • [12]Ellis PM, Shepherd FA, Millward M, et al. Daeomitinib compared with placebo in pretreated patients with advanced or metastatic non- small-cell lung cancer ( NCIC CTG BR. 26 ) : a double-blind, ran- domised, phase 3 trial[ J]. Lancet Oncol, 2014, 15 (12) : 1379- 1388. DOI: 10. 1016/S1470-2045(14)70472-3.
  • [13]Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oneogenic drivers in lung cancers to selec targeted drugs [ J . JAMA, 2014, 311 (19) : 1998-2006. DOI: 10. 1001/jama. 2014. 3741.
  • [14]Chan BA, Hughes BG. Targeted cancer: current standards and the Lung Cancer Res, 2015, 4 ( 1 ) : 2218-6751. 2014.05.01. therapy for non-small cell lung promise of the future [ J ]. Transl 36-54. DOI: 10. 3978/j. issn.
  • [15]Yagishita S, Hofinouehi H, Sunami KS, et al. Impact of KRAS mutation on response and outcome of patients with stage llI non- squaraous non-small cell lung cancer[ J 1. Cancer Sci, 2015, 106 (10) : 1402-1407. DOI: 10. 1111/cas. 12740.
  • [16]Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a rando- mised, multicentre, placebo-controlled, phase 2 study[ Jl. Lancet Oncol, 2013, 14 ( 1 ) : 38-47. DOI: 10. 1016/S1470-2045 ( 12 ) 70489-8.
  • [17]Janne PA, Smith I, McWalter G, et al. Impact of KRAS codon sub- types from a randomised phase II trial of selametinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer [ J ]. Br J Cancer, 2015, 113(2): 199-203. DOI: 10.1038/bjc. 2015.215.
  • [18]Steuer CE, Ramalingam SS. ALK-positive non-small cell lung can- cer: mechanisms of resistance and emerging treatment options [ J]. Cancer, 2014, 120(16) : 2392-2402. DOI: 10. 1002/cncr. 28597.
  • [19]Malik SM, Maher VE, Bijwaard KE, et al. USA Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive [ J]. Clin Cancer Res, 2014, 20 ( 8 ) : 2029-2034. DOI: 10. 1158/1078-0432. CCR-13-3077.
  • [20]Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer[J]. N Engl J Med, 2014, 370(13) : 1189-1197. DOI : I0. 1056/NEJMoal 311107.
  • [21]Kodama T, Tsukaguchi T, Yoshida M, et al. Selective ALK inhibi- tor alectinib with potent antitumor activity in models of crizotinib resistance[J]. Cancer Lett, 2014, 351 (2) : 215-221. DOI: 10. 1016/j. canlet. 2014.05. 020.
  • [22]Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer [ J ]. Cancer Diseov, 2014, 4(6) : 6624573. DOI: 10. 1158/2159-8290. CD-13-0846.
  • [23]Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocareinomas harboring BRAF mutations[ J]. J Clin Oncol, 2011, 29(15): 2046-2051. DOI: 10. 1200/JCO. 2010.33. 1280.
  • [24]Scagliotti G, Novello S, von Pawel J, et al. Phase m study of carbo- platin and paclitaxel alone or with sorafenib in advanced non-small- cell lung cancer[ J]. J Clin Oncol, 2010, 28 (11) : 1835-1842. DOI: 10. 1200/JCO. 2009.26. 1321.
  • [25]Joshi M, Rice S J, Liu X, et al. Trametinib with or without vemu- rafenih in BRAF mutated non-small cell lung cancer[ J ]. PIxS One, 2015, 10(2) : e0118210. DOI: 10. 1371/journal. pone. 0118210.
  • [26]Scheffler M, Schultheis A, Teixido C, et al. ROSI rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability [ J ]. Oncotarget, 2015, 6 (12) : 10577-10585. DOI : 10. 18632/oncotarget. 3387.
  • [27]Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers[ J. J Clin Oncol, 2012, 30 ( 8 ) : 863-870. DOI : 10. 1200/JCO. 2011.35. 6345.
  • [28]Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer[J]. PLoS One, 2011, 6 ( 6 ) : e20351. DOI: 10. 1371/journal. pone. 0020351.

因数据迁移导致部分文章丢失,对患者表示歉意,我们正在抓紧补救,您如果有想要资讯的问题,请联系我们医学顾问,我们会免费帮您解答!希望大家体谅!

为您推荐


版权所有·北京环宇达康医疗科技有限责任公司 京ICP备13042754号 京公网安备11010802013088

CopyrightGlobe Cancer, All Rights Reserved

提示:本网站只为患者提供疾病资讯服务和医生咨询服务,任何关于疾病的咨询建议均为参考意见,

由患者、医院和主治医师决定和实施治疗方案,本网站和咨询医师不承担由咨询行为引起的法律责任。

keywords:A45肿瘤治疗 A45肿瘤治疗 肿瘤基因检测 肿瘤基因检测 日本细胞免疫治疗 日本细胞免疫治疗 电场治疗 电场治疗 A45治疗 A45治疗 古巴肺癌疫苗 古巴肺癌疫苗 CIMAvax肺癌疫苗 CIMAvax肺癌疫苗
links: